Reportstack has announced a new market research publication on 2014 Strategies for the US Endocrine Function Testing Market which provides a comprehensive analysis in the US endocrine function market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares and strategic profiles of leading suppliers.
The report provides test volume and sales forecasts by country and market segment for the following assays: Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH, Prolactin, T3, T3 Uptake, Free T3, T4, Free T4, TBG, Testosterone, Thyroglobulin Ab, TPO Ab and TSH.
During the next five years, the endocrine function testing market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.
"2014 Strategies for the US Endocrine Function Testing Market" is a unique market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study explores future trends; provides test volume and sales forecasts; compares features of leading analyzers; and profiles key competitors.
The report provides test volume and sales forecasts by country and market segment for the following assays: Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH, Prolactin, T3, T3 Uptake, Free T3, T4, Free T4, TBG, Testosterone, Thyroglobulin Ab, TPO Ab and TSH.
During the next five years, the endocrine function testing market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.
"2014 Strategies for the US Endocrine Function Testing Market" is a unique market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study explores future trends; provides test volume and sales forecasts; compares features of leading analyzers; and profiles key competitors.
The Companies Mentioned in this report are
Abbott Laboratories
AdnaGen
Agilent Technologies
Beckman Coulter/Danaher
Biomedical Diagnostics
BioMerieux
Bio-Rad
DiaSorin
Eiken
Fujirebio/Innogenetics
Instrumentation Laboratory
Kyowa Medex
Matritech/Alere
Ortho-Clinical Diagnostics
Quest Diagnostics
Roche
Siemens
Sysmex
Thermo Fisher
Tosoh
Wako
Wallac/PE
AdnaGen
Agilent Technologies
Beckman Coulter/Danaher
Biomedical Diagnostics
BioMerieux
Bio-Rad
DiaSorin
Eiken
Fujirebio/Innogenetics
Instrumentation Laboratory
Kyowa Medex
Matritech/Alere
Ortho-Clinical Diagnostics
Quest Diagnostics
Roche
Siemens
Sysmex
Thermo Fisher
Tosoh
Wako
Wallac/PE
To view the table of contents and know more details please visit 2014 Strategies for the US Endocrine Function Testing Market.
No comments:
Post a Comment